he Australian consumer watchdog agency is taking Novartis (NVS) and GlaxoSmithKline (GSK) to court for allegedly false or misleading marketing about a pair of gels used to treat pain.

The move is the latest by the Australian Competition and Consumer Commission to crack down on drug makers for making “misleading representations” about their products. Last year, the agency fined Reckitt Benckiser $4.5 million for deceptive practices in promoting a pain medication.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Reply to Observer079 Cancel reply

Please enter your name.
Please enter a comment.

  • If fading memory serves, Voltaren was ‘a hot new US product’ for CibaGeigy 30 years ago. A new meaning to ‘evergreening!’

Recommended Stories

Pharmaceutical production
Drug Pricing

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.